154 related articles for article (PubMed ID: 25711229)
21. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
Yang M; Xu SP; Ao QL
Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
[TBL] [Abstract][Full Text] [Related]
22. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
Latta EK; Tjan S; Parkes RK; O'Malley FP
Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical COX-2 overexpression correlates with HER-2/neu overexpression in invasive breast carcinomas: a pilot study.
Çiriş IM; Bozkurt KK; Başpinar S; Kapucuoğlu FN
Pathol Res Pract; 2011 Mar; 207(3):182-7. PubMed ID: 21371829
[TBL] [Abstract][Full Text] [Related]
24. [Histological grading in ductal carcinoma in situ of the breast].
Xu W; Zhu X; Zhang T; Tu X; Shi D
Zhonghua Bing Li Xue Za Zhi; 1999 Oct; 28(5):331-3. PubMed ID: 11869542
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study.
Altintas S; Lambein K; Huizing MT; Braems G; Asjoe FT; Hellemans H; Van Marck E; Weyler J; Praet M; Van den Broecke R; Vermorken JB; Tjalma WA
Breast J; 2009; 15(2):120-32. PubMed ID: 19292797
[TBL] [Abstract][Full Text] [Related]
26. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.
Barnes NL; Khavari S; Boland GP; Cramer A; Knox WF; Bundred NJ
Clin Cancer Res; 2005 Mar; 11(6):2163-8. PubMed ID: 15788662
[TBL] [Abstract][Full Text] [Related]
27. Expression of COX-2, p16, and Ki67 in the range from normal breast tissue to breast cancer.
Feriancová M; Walter I; Singer CF; Gazdarica J; Pohlodek K
Neoplasma; 2021 Mar; 68(2):342-351. PubMed ID: 33147051
[TBL] [Abstract][Full Text] [Related]
28. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
29. P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ.
Paredes J; Lopes N; Milanezi F; Schmitt FC
Virchows Arch; 2007 Jan; 450(1):73-80. PubMed ID: 17123107
[TBL] [Abstract][Full Text] [Related]
30. Ductal carcinoma in situ of the breast: correlation between histopathological features and age of patients.
Perez AA; Balabram D; Salles Mde A; Gobbi H
Diagn Pathol; 2014 Dec; 9():227. PubMed ID: 25471940
[TBL] [Abstract][Full Text] [Related]
31. COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ.
Boland GP; Butt IS; Prasad R; Knox WF; Bundred NJ
Br J Cancer; 2004 Jan; 90(2):423-9. PubMed ID: 14735188
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathological analysis of breast ductal carcinoma in situ with ALDH1-positive cancer stem cells.
Tsukabe M; Shimazu K; Morimoto K; Naoi Y; Kagara N; Shimoda M; Shimomura A; Maruyama N; Kim SJ; Noguchi S
Oncology; 2013; 85(4):248-56. PubMed ID: 24192633
[TBL] [Abstract][Full Text] [Related]
33. Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast.
Vincent-Salomon A; Lucchesi C; Gruel N; Raynal V; Pierron G; Goudefroye R; Reyal F; Radvanyi F; Salmon R; Thiery JP; Sastre-Garau X; Sigal-Zafrani B; Fourquet A; Delattre O;
Clin Cancer Res; 2008 Apr; 14(7):1956-65. PubMed ID: 18381933
[TBL] [Abstract][Full Text] [Related]
34. Are the pure in situ breast ductal carcinomas and those associated with invasive carcinoma the same?
Schorr MC; Pedrini JL; Savaris RF; Zettler CG
Appl Immunohistochem Mol Morphol; 2010 Jan; 18(1):51-4. PubMed ID: 19568168
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathological Significance of the Proliferation Markers Ki67, RacGAP1, and Topoisomerase 2 Alpha in Breast Cancer.
Şahin S; Işık Gönül İ; Çakır A; Seçkin S; Uluoğlu Ö
Int J Surg Pathol; 2016 Oct; 24(7):607-13. PubMed ID: 27284123
[TBL] [Abstract][Full Text] [Related]
36. Distribution pattern of Ki67 immunoreactivity in ductal intraepithelial neoplasia: Correlation with lesion grade and potential utility.
Ozerdem U; Tavassoli FA
Pathol Res Pract; 2016 Oct; 212(10):872-875. PubMed ID: 27499154
[TBL] [Abstract][Full Text] [Related]
37. Relationship between nuclear grade of ductal carcinoma in situ and cell origin markers.
Tang P; Wang X; Schiffhauer L; Wang J; Bourne P; Yang Q; Quinn A; Hajdu SI
Ann Clin Lab Sci; 2006; 36(1):16-22. PubMed ID: 16501232
[TBL] [Abstract][Full Text] [Related]
38. Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers.
van der Groep P; van Diest PJ; Menko FH; Bart J; de Vries EG; van der Wall E
J Clin Pathol; 2009 Oct; 62(10):926-30. PubMed ID: 19541683
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathologic features of ductal carcinoma in situ in young women with an emphasis on molecular subtype.
VandenBussche CJ; Elwood H; Cimino-Mathews A; Bittar Z; Illei PB; Warzecha HN
Hum Pathol; 2013 Nov; 44(11):2487-93. PubMed ID: 24029706
[TBL] [Abstract][Full Text] [Related]
40. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.
Borgquist S; Zhou W; Jirström K; Amini RM; Sollie T; Sørlie T; Blomqvist C; Butt S; Wärnberg F
BMC Cancer; 2015 Jun; 15():468. PubMed ID: 26062614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
